In conclusion, the novel H&E-based histopathological SARIFA-status maintained its prognostic value even within molecular subgroups based on BRAF, RAS, and MMR status, which proves the potential of SARIFA-status to improve stratification of CRC patients even beyond clinically already ﻿used molecular tests. This evidence concerns the gene BRAF and colorectal carcinoma.